论文部分内容阅读
目的观察曲美他嗪联合瑞舒伐他汀治疗缺血性心肌病心力衰竭的临床效果。方法将医院收治的缺血性心肌病心力衰竭患者80例随机分为对照组和观察组,每组40例。对照组采用常规抗心力衰竭治疗同时口服瑞舒伐他汀治疗,观察组在对照组基础上口服曲美他嗪治疗。1个疗程后比较2组左室收缩末期容积(LVESV)、左室舒张末期容积(LVEDV)、左心室射血分数(LVEF)、6分钟步行试验(6MWT)结果及总好转率。结果经1个疗程治疗后,2组LVESV、LVEDV、LVEF、6MWT数值较治疗前均好转(P<0.05);观察组治疗后LVESV、LVEDV、LVEF、6MWT数值均优于对照组(P<0.05)。观察组总好转率为97.50%,高于对照组的75.00%(P<0.05)。结论缺血性心肌病心力衰竭患者采用曲美他嗪和瑞舒伐他汀联合治疗效果显著。
Objective To observe the clinical effect of trimetazidine combined with rosuvastatin on heart failure of ischemic cardiomyopathy. Methods 80 cases of ischemic cardiomyopathy hospitalized patients with heart failure were randomly divided into control group and observation group, 40 cases in each group. The control group was treated with conventional anti-heart failure and oral rosuvastatin. The observation group was treated with trimetazidine orally on the basis of the control group. After one course of treatment, LVESV, LVEDV, LVEF, 6MWT (6MWT) and total improvement rate were compared between the two groups. Results After 1 course of treatment, the values of LVESV, LVEDV, LVEF and 6MWT in both groups were significantly improved (P <0.05), and the values of LVESV, LVEDV, LVEF and 6MWT in the observation group were better than those in the control group ). The improvement rate of the observation group was 97.50%, which was higher than that of the control group (75.00%, P <0.05). Conclusion Patients with ischemic cardiomyopathy heart failure using trimetazidine and rosuvastatin combination therapy was significant.